Welcome to the AxBlog. sign up for updates Bithia Anderson 3/4/25 Bithia Anderson 3/4/25 Navigating the Complex Landscape of Gene and Cell Therapies: A Strategic Guide for Employers Read More Bithia Anderson 3/4/25 Bithia Anderson 3/4/25 The Future is Now: RNA Therapies and Your Benefit Strategy Read More Bithia Anderson 1/28/25 Bithia Anderson 1/28/25 2024 FDA Drug Approvals: The Continued Rise of Specialty Medications Read More Bithia Anderson 1/16/25 Bithia Anderson 1/16/25 Employers’ Guide to Navigating AI in Pharmacy Benefits: Balancing Innovation and Accountability Read More Bithia Anderson 1/16/25 Bithia Anderson 1/16/25 Own the Outcome: Employers Hold the Key to Specialty Drug Management Success Read More Bithia Anderson 1/10/25 Bithia Anderson 1/10/25 FDA New Drug Approvals: November-December 2024 Read More Bithia Anderson 1/10/25 Bithia Anderson 1/10/25 FDA New Drug Approvals: August–October 2024 Read More Bithia Anderson 8/8/24 Bithia Anderson 8/8/24 The Impact of GLP-1 and GLP-1/GIP Medications on Weight Management and Employer Costs Read More Bithia Anderson 8/8/24 Bithia Anderson 8/8/24 FDA New Drug Approvals: May–July 2024 Read More Bithia Anderson 5/16/24 Bithia Anderson 5/16/24 Abstract: Evaluation and Comparison of Prior Authorization Policies for Specialty Drugs Read More Bithia Anderson 5/10/24 Bithia Anderson 5/10/24 April 2024 New Drug Approvals Read More Bithia Anderson 4/4/24 Bithia Anderson 4/4/24 Top Specialty Drug Management Goals for Employers: Emphasis on Patient-Centered Approach Read More Bithia Anderson 3/28/24 Bithia Anderson 3/28/24 The Importance of Proactive Pipeline Management in Specialty Drug Formulary Strategies Read More Bithia Anderson 3/18/24 Bithia Anderson 3/18/24 2024 New Drug Approvals: January & February Read More Bithia Anderson 3/18/24 Bithia Anderson 3/18/24 December 2023 New Drug Approvals Read More Bithia Anderson 3/18/24 Bithia Anderson 3/18/24 November 2023 New Drug Approvals Read More Bithia Anderson 3/18/24 Bithia Anderson 3/18/24 October 2023 New Drug Approvals Read More Bithia Anderson 3/18/24 Bithia Anderson 3/18/24 September 2023 New Drug Approvals Read More Bithia Anderson 3/15/24 Bithia Anderson 3/15/24 Trends in Specialty Drug Approvals & Management: A Look at 2021-2024 Read More Bithia Anderson 9/1/23 Bithia Anderson 9/1/23 August 2023 New Drug Approvals Read More Older Posts Start your journey with Axum
Bithia Anderson 3/4/25 Bithia Anderson 3/4/25 Navigating the Complex Landscape of Gene and Cell Therapies: A Strategic Guide for Employers Read More
Bithia Anderson 3/4/25 Bithia Anderson 3/4/25 The Future is Now: RNA Therapies and Your Benefit Strategy Read More
Bithia Anderson 1/28/25 Bithia Anderson 1/28/25 2024 FDA Drug Approvals: The Continued Rise of Specialty Medications Read More
Bithia Anderson 1/16/25 Bithia Anderson 1/16/25 Employers’ Guide to Navigating AI in Pharmacy Benefits: Balancing Innovation and Accountability Read More
Bithia Anderson 1/16/25 Bithia Anderson 1/16/25 Own the Outcome: Employers Hold the Key to Specialty Drug Management Success Read More
Bithia Anderson 1/10/25 Bithia Anderson 1/10/25 FDA New Drug Approvals: November-December 2024 Read More
Bithia Anderson 1/10/25 Bithia Anderson 1/10/25 FDA New Drug Approvals: August–October 2024 Read More
Bithia Anderson 8/8/24 Bithia Anderson 8/8/24 The Impact of GLP-1 and GLP-1/GIP Medications on Weight Management and Employer Costs Read More
Bithia Anderson 5/16/24 Bithia Anderson 5/16/24 Abstract: Evaluation and Comparison of Prior Authorization Policies for Specialty Drugs Read More
Bithia Anderson 4/4/24 Bithia Anderson 4/4/24 Top Specialty Drug Management Goals for Employers: Emphasis on Patient-Centered Approach Read More
Bithia Anderson 3/28/24 Bithia Anderson 3/28/24 The Importance of Proactive Pipeline Management in Specialty Drug Formulary Strategies Read More
Bithia Anderson 3/18/24 Bithia Anderson 3/18/24 2024 New Drug Approvals: January & February Read More
Bithia Anderson 3/15/24 Bithia Anderson 3/15/24 Trends in Specialty Drug Approvals & Management: A Look at 2021-2024 Read More
